Semaglutide vs Tirzepatide: Research Overview

What is the difference between semaglutide and tirzepatide?

The core difference is receptor targeting. Semaglutide is a single-receptor compound that acts as an agonist at the GLP-1 (glucagon-like peptide-1) receptor only. Tirzepatide is a dual-receptor compound that acts as an agonist at both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which is why it is often described in the literature as a twincretin.

Beyond receptor targeting, the two differ in peptide sequence, structural engineering and reported pharmacokinetics. This article summarises those differences for laboratory research reference only. The compounds discussed here are research-grade materials intended strictly for in-vitro and laboratory investigation, and are not the approved pharmaceutical products.

Receptor pharmacology: single versus dual incretin targeting

The clearest axis of comparison between these two molecules is how many incretin receptors each engages.

Semaglutide is a selective GLP-1 receptor agonist. Published pharmacology describes binding and activation at the GLP-1 receptor without meaningful activity at the GIP receptor. Tirzepatide, by contrast, engages two receptors. It is reported in the peer-reviewed literature as an agonist at both the GIP receptor and the GLP-1 receptor, and some studies characterise its activity across the two receptors as imbalanced rather than equal.

The practical research distinction is often framed as mono-incretin versus dual-incretin activity:

• Semaglutide: GLP-1 receptor agonist (single incretin pathway).
• Tirzepatide: GIP and GLP-1 receptor agonist (dual incretin pathway, a twincretin).
• GLP-1 and GIP are both members of the incretin hormone family, but they signal through distinct receptors.

Molecular class and structural differences

Both compounds are peptide analogues engineered from native incretin hormone sequences, but their origins and modifications differ.

Semaglutide is an analogue of human GLP-1. A commonly cited structural feature is the substitution at position 8 with a non-coded amino acid, 2-aminoisobutyric acid (Aib), which is reported to reduce degradation by the DPP-4 enzyme while preserving affinity for the GLP-1 receptor. Semaglutide also carries a fatty-acid side chain that supports albumin binding.

Tirzepatide is described in the literature as a 39-amino-acid synthetic peptide engineered from the GIP sequence and modified to engage the GLP-1 receptor as well. Like semaglutide, it includes an acyl (fatty-acid) chain that contributes to albumin binding. The sequences and the specific chemical modifications are distinct between the two molecules, so they are not interchangeable at a structural level.

Half-life and pharmacokinetics

Both molecules are engineered for extended circulation through albumin binding, but the reported half-lives differ.

Published pharmacokinetic data describe semaglutide with a half-life of approximately one week (around 165 hours), which is frequently cited as the basis for once-weekly dosing in the approved pharmaceutical products. Tirzepatide is reported with a shorter half-life of roughly five days (approximately 120 hours), which likewise supports a once-weekly profile in its approved product.

Both figures reflect class-level engineering for extended circulation rather than any claim about the research-grade material itself.

• Semaglutide reported half-life: approximately 1 week (around 165 hours).
• Tirzepatide reported half-life: approximately 5 days (around 120 hours).
• Both rely on fatty-acid side chains and albumin binding to extend circulation time.

Regulatory status in Australia

It is important to separate the approved pharmaceutical products from research-grade material, because they are not the same thing.

Semaglutide is the active ingredient in medicines approved by the TGA and listed on the ARTG, marketed under brand names including Ozempic and Wegovy. Tirzepatide is the active ingredient in Mounjaro, which Eli Lilly Australia has registered on the ARTG; public TGA assessment material describes Australian indications that include insufficiently controlled type 2 diabetes and chronic weight management, each with their own criteria. These are prescription medicines and any reference to their approved indications here is purely factual and neutral.

Research-grade semaglutide and research-grade tirzepatide are handled as laboratory reference materials on a research-use-only basis. They are not the approved pharmaceutical products, they are not substitutes for them, and nothing in this article describes or endorses any use in humans or animals. For a focused look at the legal framing of each compound, see the pages below.

Is semaglutide legal in Australia? Is tirzepatide legal in Australia?

Anti-doping (WADA) context

For researchers working in sports-science or anti-doping-adjacent settings, it is worth noting the anti-doping framing around incretin-class compounds in a neutral way.

Compounds that act on metabolic and incretin pathways can fall within the scope of anti-doping review depending on how the World Anti-Doping Agency (WADA) classifies and updates its lists over time. Because WADA status can change between annual list revisions, researchers should always consult the current official WADA documentation directly rather than relying on a static summary. This overview does not assert a specific prohibited-list status for either molecule.

Summary comparison at a glance

The table-style summary below consolidates the main research reference points discussed above.

• Receptor target: semaglutide acts on GLP-1 only; tirzepatide acts on GLP-1 and GIP.
• Class label: semaglutide is a GLP-1 analogue; tirzepatide is a dual GIP/GLP-1 agonist (twincretin).
• Structure: distinct peptide sequences, both with albumin-binding fatty-acid side chains.
• Reported half-life: semaglutide around 1 week; tirzepatide around 5 days.
• Australian regulatory status: both have approved prescription products on the ARTG (Ozempic/Wegovy and Mounjaro respectively); research-grade material is separate and research-use-only.
• Interchangeability: the two are structurally and pharmacologically distinct and are not equivalent.